Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Unknown × Uterine Cervical Neoplasms × zimberelimab × Clear all

Phase

Status

Recruiting 2 Not yet recruiting 2 Active not recruiting 2 Unknown 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Uterine Cervical Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Biliary Carcinoma 1

Interventions

Cisplatin 39 Radiotherapy 18 Brachytherapy 16 Paclitaxel 15 Carboplatin 15 Bevacizumab 6 Drug Therapy 5 toripalimab 4 camrelizumab 4 Neoadjuvant Therapy 4 Gemcitabine 4 tislelizumab 3 pembrolizumab 3 nimotuzumab 3 apatinib 3 Vaccines 3 TP protocol 3 Radiation 3 nedaplatin 2 anlotinib 2 Topotecan 2 Surgical Procedures, Operative 2 Radiotherapy, Intensity-Modulated 2 Mindfulness 2 Mass Screening 2 Interleukin-2 2 Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 2 Docetaxel 2 Diathermy 2 DNA Methylation 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03972722 2019-06-05

CC

Guangzhou Gloria Biosciences Co., Ltd.

Phase 2 Unknown

Uterine Cervical Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡